Kevin Fitzgerald

21.7k total citations · 8 hit papers
83 papers, 10.6k citations indexed

About

Kevin Fitzgerald is a scholar working on Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Kevin Fitzgerald has authored 83 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 13 papers in Genetics and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Kevin Fitzgerald's work include RNA Interference and Gene Delivery (15 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Advanced biosensing and bioanalysis techniques (8 papers). Kevin Fitzgerald is often cited by papers focused on RNA Interference and Gene Delivery (15 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Advanced biosensing and bioanalysis techniques (8 papers). Kevin Fitzgerald collaborates with scholars based in United States, United Kingdom and Germany. Kevin Fitzgerald's co-authors include Iva Greenwald, Martin A. Maier, Akin Akinc, Victor Koteliansky, Anna Borodovsky, William Querbes, Gary Struhl, Maria Frank-Kamenetsky, Nada Y. Kalaany and David M. Sabatini and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Kevin Fitzgerald

82 papers receiving 10.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape

2013 1.2k citations Jérôme Gilleron, William Querbes et al. Nature Biotechnology profile →
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

2019 1.2k citations Akin Akinc, Martin A. Maier et al. Nature Nanotechnology profile →
Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1

2006 1.2k citations David A. Guertin, Deanna M. Stevens et al. Developmental Cell profile →
Lipid-like materials for low-dose, in vivo gene silencing

2010 792 citations William Querbes, June Qin et al. Proceedings of the National Academy of Sciences profile →
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

2016 586 citations Kevin Fitzgerald, Anna Borodovsky et al. profile →
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

2013 467 citations Kevin Fitzgerald, Maria Frank-Kamenetsky et al. profile →
Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure

2016 328 citations Hendrik B. Sager, Timo Heidt et al. profile →
RNA interference in the era of nucleic acid therapeutics

2024 103 citations Akshay Vaishnaw, Kevin Fitzgerald et al. Nature Biotechnology profile →

Peers

Countries citing papers authored by Kevin Fitzgerald

Since Specialization

Citations

This map shows the geographic impact of Kevin Fitzgerald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Fitzgerald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Fitzgerald more than expected).

Fields of papers citing papers by Kevin Fitzgerald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Fitzgerald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Fitzgerald. The network helps show where Kevin Fitzgerald may publish in the future.

Co-authorship network of co-authors of Kevin Fitzgerald

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Fitzgerald. A scholar is included among the top collaborators of Kevin Fitzgerald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Fitzgerald. Kevin Fitzgerald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities 2025 ·Journal of Experimental & Clinical Cancer Research ·Lais C. G. F. Palhares, Melanie Grandits, (unknown), Jitesh Chauhan, (unknown), Gilbert O. Fruhwirth, Sophia Tsoka, James R. Birtley, Leanne Partington, T. Wilson, Elizabeth Hardaker, Sophia N. Karagiannis, Heather J. Bax, Kevin Fitzgerald	1
2	Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis 2020 ·Neurology ·Simina Ticau, Gautham Sridharan, (unknown), William Cantley, Amy Chan, Jason A. Gilbert, David V. Erbe, Emre Aldinc, Mary M. Reilly, David Adams, Michael Polydefkis, Kevin Fitzgerald, Akshay Vaishnaw, Paul Nioi	72
3	Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence 2020 ·BMC Cancer ·Jennifer L. S. Willoughby, Kelly M. George, Mark P. Roberto, Hang Gyeong Chin, (unknown), Hyunjin Shin, Chandra Sekhar Pedamallu, Scott E. Schaus, Kevin Fitzgerald, Jagesh V. Shah, Ulla Hansen	12
4	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs breakdown → 2019 ·Nature Nanotechnology ·Akin Akinc, Martin A. Maier, Muthiah Manoharan, Kevin Fitzgerald, Muthusamy Jayaraman, Scott Barros, Steven M. Ansell, Xinyao Du, Michael J. Hope, Thomas D. Madden, Barbara L. Mui, Sean C. Semple, Ying K. Tam, Marco A. Ciufolini, Dominik Witzigmann, Jayesh A. Kulkarni, Roy van der Meel, Pieter R. Cullis	1160
5	Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis 2019 ·Molecular Therapy — Methods & Clinical Development ·Linda L. Kusner, Kristina Yucius, Manjistha Sengupta, Andrew Sprague, (unknown), Tuyen Nguyen, Klaus Charissé, Satya Kuchimanchi, (unknown), Kevin Fitzgerald, Henry J. Kaminski, Anna Borodovsky	42
6	An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema 2018 ·RNA ·Jingxuan Liu, June Qin, Anna Borodovsky, Timothy Racie, Adam Castoreno, Mark K. Schlegel, Martin A. Maier, (unknown), Kevin Fitzgerald, James Butler, Akin Akinc	32
7	Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling 2017 ·Journal of Clinical Investigation ·Samir Softic, Manoj K. Gupta, (unknown), Shiho Fujisaka, Brian T. O’Neill, Tata Nageswara Rao, Jennifer L. S. Willoughby, Carole E. Harbison, Kevin Fitzgerald, Olga Ilkayeva, Christopher B. Newgard, David E. Cohen, C. Ronald Kahn	261
8	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation 2017 ·Cell Metabolism ·Chai-Wan Kim, Carol Addy, Jun Kusunoki, Norma N. Anderson, Stanisław Deja, Xiaorong Fu, Shawn C. Burgess, Li Cai, (unknown), Manu V. Chakravarthy, (unknown), Stuart Milstein, Kevin Fitzgerald, David E. Kelley, Jay D. Horton	314
9	Identification of siRNA delivery enhancers by a chemical library screen 2015 ·Nucleic Acids Research ·Jérôme Gilleron, (unknown), Anja Zeigerer, William Querbes, Giovanni Marsico, Cordula Andree, Sarah Seifert, Pablo Amaya, Martin Stöter, Victor Koteliansky, Herbert Waldmann, Kevin Fitzgerald, Yannis Kalaidzidis, Akin Akinc, Martin A. Maier, Muthiah Manoharan, Marc Bickle, Marino Zerial	59
10	Hepatocyte‐Specific Delivery of siRNAs Conjugated to Novel Non‐nucleosidic Trivalent N‐Acetylgalactosamine Elicits Robust Gene Silencing in Vivo 2015 ·ChemBioChem ·Kallanthottathil G. Rajeev, Jayaprakash K. Nair, Muthusamy Jayaraman, Klaus Charissé, Nate Taneja, Jonathan O′Shea, Jennifer L. S. Willoughby, Kristina Yucius, Tuyen Nguyen, Svetlana Shulga‐Morskaya, Stuart Milstein, Abigail Liebow, William Querbes, Anna Borodovsky, Kevin Fitzgerald, Martin A. Maier, Muthiah Manoharan	148
11	Abstract 15574: A Subcutaneous Platform for RNAi Therapeutics Targeting ANGPTL3 2013 ·Circulation ·William Querbes, Scott Barros, Renta Hutabarat, Stuart Milstein, (unknown), Satya Kuchimanchi, Klaus Charissé, Rachel A. Myers, Muthiah Manoharan, Martin A. Maier, Kevin Fitzgerald	1
12	Liver as a target for oligonucleotide therapeutics 2013 ·Journal of Hepatology ·Alfica Sehgal, Akshay Vaishnaw, Kevin Fitzgerald	93
13	In Vivo Silencing of the Transcription Factor IRF5 Reprograms the Macrophage Phenotype and Improves Infarct Healing 2013 ·Journal of the American College of Cardiology ·Gabriel Courties, Timo Heidt, Matthew Sebas, Yoshiko Iwamoto, (unknown), Jessica Truelove, Benoit Tricot, Gregory R. Wojtkiewicz, Partha Dutta, Hendrik B. Sager, Anna Borodovsky, Tatiana I. Novobrantseva, Boris Klebanov, Kevin Fitzgerald, Daniel G. Anderson, Peter Libby, Filip K. Świrski, Ralph Weissleder, Matthias Nahrendorf	227
14	Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape breakdown → 2013 ·Nature Biotechnology ·Jérôme Gilleron, William Querbes, Anja Zeigerer, Anna Borodovsky, Giovanni Marsico, Undine Schubert, K. Manygoats, Sarah Seifert, Cordula Andree, Martin Stöter, Hila Epstein-Barash, Ligang Zhang, Victor Koteliansky, Kevin Fitzgerald, Eugenio Fava, Marc Bickle, Yannis Kalaidzidis, Akin Akinc, Martin A. Maier, Marino Zerial	1232
15	The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals 2012 ·Cell Metabolism ·Young-Ah Moon, Guosheng Liang, Xuefen Xie, Maria Frank-Kamenetsky, Kevin Fitzgerald, Victor Koteliansky, Michael S. Brown, Joseph L. Goldstein, Jay D. Horton	264
16	Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1 breakdown → 2006 ·Developmental Cell ·David A. Guertin, Deanna M. Stevens, Carson C. Thoreen, Aurora A. Burds, Nada Y. Kalaany, Jason Moffat, Michael Brown, Kevin Fitzgerald, David M. Sabatini	1158
17	CIS display: In vitro selection of peptides from libraries of protein–DNA complexes 2004 ·Proceedings of the National Academy of Sciences ·(unknown), David Coomber, (unknown), (unknown), Philip A. Kuhlman, Christopher G. Ullman, Kevin Fitzgerald, Duncan McGregor	114
18	CD3� anti-nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors 1999 ·International Journal of Cancer ·Oliver Manzke, Kevin Fitzgerald, Philipp Holliger, (unknown), (unknown), Bernd K. Fleischmann, Juergen Hescheler, Qinghua Liu, Kevin S. Johnson, Volker Diehl, Hennie R. Hoogenboom, Heribert Bohlen	12
19	Phage diabody repertoires for selection of large numbers of bispecific antibody fragments 1996 ·Nature Biotechnology ·Brian McGuinness, Gerald Walter, Kevin Fitzgerald, (unknown), Walt Mahoney, Alexander Duncan, Hennie R. Hoogenboom	57
20	Sequence analysis of immunoglobulin heavy-chain variable region genes from the synovium of a rheumatoid arthritis patient shows little evidence of mutation but diverse CDR3. 1995 ·PubMed Central ·Christina Brown, Kevin Fitzgerald, (unknown), Rizgar A. Mageed, (unknown), Ravinder N. Maini	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact